Education
About Us
Working with TipRanks
Follow Us
Can-Fite BioPharma (CANF)
:CANF
CANF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.60 - $3.12
Previous CloseN/A
Volume35.97K
Average Volume (3M)155.49K
Market Cap
$14.09M
Enterprise Value$5.58M
Total Cash (Recent Filing)$7.89M
Total Debt (Recent Filing)$104.00K
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 21, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding15,772,915
10 Day Avg. Volume190,982
30 Day Avg. Volume155,486
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue8.27
Enterprise Value/Gross Profit8.27
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$0.50Price Target Upside-19.35% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering0
Can-Fite BioPharma News
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $0.60 and its highest was $3.12 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Can-Fite BioPharma’s market cap is $14.09M.
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is Nov 21, 2025 which is in 54 days.
How were Can-Fite BioPharma’s earnings last quarter?
Can-Fite BioPharma released its earnings results on Aug 28, 2025. The company reported -$0.144 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.034.
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Overvalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate is -0.14.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 15,772,915 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Can-Fite BioPharma reported an EPS of -$0.144 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
5.05% Other Institutional Investors
94.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---